Is Janux Therapeutics, Inc. (JANX) Overvalued?
We dive into why Janux Therapeutics, Inc. (JANX) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Commentary & Analysis
Why Janux Therapeutics, Inc.’s (JANX) Stock Is Down 5.84%
As of Tuesday, July 28, Janux Therapeutics, Inc.’s JANX share price has dipped by 5.84%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Janux Therapeutics, Inc.’s (JANX) Stock Is Up 5.42%
As of Friday, June 26, Janux Therapeutics, Inc.’s JANX share price has surged by 5.42%, which has investors questioning if this is right time to sell.Jenna Brashear
What You Need to Know About Janux Therapeutics, Inc.'s Q2 Earnings
Janux Therapeutics, Inc.'s fiscal Q2 earnings report was released on Thursday, May 07. Let's dive in to see if (JANX) missed or beat analyst's expectations.Michael Rose
Why Janux Therapeutics, Inc.’s (JANX) Stock Is Up 5.30%
As of Tuesday, March 31, Janux Therapeutics, Inc.’s JANX share price has surged by 5.30%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | JANX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,063.2 | $292.6 | 45% |
|
| Shares Out (Mil) | 62.9 | 54.4 | 53% |
|
| Institutional Ownership | 92.8% | 93.2% | 62% |
|
| Float (Mil) | 42.5 | 40.2 | 44% |
|
| Beta | 2.51 | 0.94 | 96% |
|
| Avg Daily Volume (000s) | 694 | 544 | 63% |
|
| Price Change (52-week) |
(30.1%) | 59.7% | 23% |
|
| Growth | JANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (75.6%) | (10.1%) | 3% |
|
| EPS (5yr) | 24.4% | 16.0% | 74 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (22.7%) | (15.6%) | 29% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 13 | 13 | 12 | |
| Current EPS | ($0.500) | ($1.758) | ($2.639) | |
| Month Ago EPS | ($0.518) | ($1.765) | ($2.698) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 4 | 1 | 1 | |
| Three Months Ago EPS | ($0.518) | ($1.790) | ($2.773) | |
| Year/Year Chg | 43.3% | (4.1%) | 80.2% | |
| Financials | JANX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $24 | $37 | 14% |
|
| Net Income (TTM) (Mil) | ($103) | ($43) | 11% |
|
| EPS (TTM) | ($1.643) | ($1.400) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($41) | ($31) | 11% |
|
| Net Cash Flow (TTM) (Mil) | ($25) | $2 | 24% |
|
| Long-Term Debt (Q1) (Mil) | $18 | $4 | 32% |
|
| Enterprise Value (Q1) (Mil) | $19 | $164 | 11% |
|
| Valuation | JANX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.14 | 2.83 | 26% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | JANX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (416.6%) | 64.2% | 1% |
|
| Net Margin | (427.5%) | (75.9%) | 2% |
|
| ROA | (10.1%) | (47.5%) | 25% |
|
| ROE | (10.7%) | (55.0%) | 27% |
|
| Liabilities to Assets | 7.9% | 29.6% | 4% |
|
| F-Score | 3 | 3 | 18% |
|
Janux Therapeutics, Inc. did not pass any screens on 8/21/2026.
